Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II GCD9 trial of gemcitabine + cisplatin + durvalumab for unresectable biliary tract cancer
jRCTs051240067Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, cisplatin and durvalumab in biliary cancer, intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA) and 1 more, sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Jul 2024; status: active, not recruiting.
02
Drugs
gemcitabinecisplatindurvalumab
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancer
Beyond the preview
Go deeper on jRCTs051240067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240067.